Beyond Weight Loss: Can GLP-1 Medications Support Healthy Aging?
GLP-1 medications have changed the conversation about weight management. For many patients, treatments such as Wegovy and Ozempic have made meaningful weight loss possible after years of struggling. But researchers are now exploring a broader question: could the metabolic improvements associated with these medications also help us stay healthier as we age?
In our practice, we are interested in more than pounds lost. We want to understand what treatment means for your cardiovascular health, body composition, physical strength, and risk of chronic disease. That is why research connecting semaglutide with reduced inflammation and changes in biological aging markers deserves attention.
The findings are promising. Understanding what they show—and what remains unanswered—helps us make thoughtful decisions about your care.
Looking Beyond the Scale
Excess body fat, particularly visceral fat stored deep within the abdomen, can affect health in ways that are not visible on a bathroom scale. This fat surrounds internal organs and contributes to metabolic changes associated with cardiovascular disease, type 2 diabetes, and fatty liver disease.
When we evaluate a weight management plan, we therefore consider more than your weight. We also look at factors such as your waist measurements, blood pressure, blood sugar, cholesterol, muscle mass, and overall well-being.
Semaglutide, the active ingredient in Wegovy and Ozempic, mimics the action of glucagon-like peptide-1, a hormone involved in appetite and blood sugar regulation. Researchers are studying whether its effects on metabolic health might also influence processes involved in aging.
Two terms help frame this discussion. Lifespan refers to how long a person lives. Healthspan refers to the years spent in good health, with the ability to remain active and independent. In our practice, supporting healthspan means helping you protect the health and physical capacity that allow you to enjoy your life.
Why Inflammation Matters
Inflammation is a necessary part of the body’s defense and repair system. When you have an injury or infection, a temporary inflammatory response helps you heal.
The concern is inflammation that persists over time. Chronic, low-grade inflammation is associated with several conditions that become more common with age, including cardiovascular disease and metabolic disorders.
Visceral fat can contribute to this process by releasing inflammatory signaling molecules. This is one reason researchers are interested in how treatments that reduce excess body fat may affect inflammation.
An analysis of the randomized STEP 1, 2, and 3 clinical trials examined the effects of semaglutide on C-reactive protein, or CRP, a blood marker of inflammation. Over 68 weeks, participants receiving semaglutide 2.4 mg weekly had greater reductions in CRP than those receiving placebo. Improvements were associated with changes in weight and metabolic measures. [1]
These findings support an effect on an inflammatory marker. They do not, by themselves, establish that semaglutide slows aging. Researchers are still working to determine how much of the change results from weight loss and how much may reflect other actions of the medication.
When appropriate, we may include high-sensitivity CRP, or hsCRP, in a patient’s assessment. We interpret it alongside medical history and other findings because it is a nonspecific marker: it does not identify the cause of inflammation or directly measure aging.
What the New Aging Research Found
A study published in Nature Communications in May 2026 explored semaglutide’s effects on biological aging markers. Researchers analyzed blood samples from 84 adults in a 32-week randomized, placebo-controlled trial involving HIV-associated lipohypertrophy, a condition characterized by abnormal fat accumulation. Forty-five participants received semaglutide and 39 received placebo. [2]
The researchers used epigenetic clocks—tools that analyze chemical patterns on DNA to estimate aspects of biological aging. Participants receiving semaglutide showed favorable changes in several of these measures. One, called DunedinPACE, suggested an approximately 9% slower pace of aging compared with placebo in adjusted analyses. [2]
This is an interesting early finding, but the distinction between a research marker and a demonstrated health benefit matters. A change in an epigenetic clock does not mean a person will live longer, or will necessarily have better memory, strength, or organ function.
The analysis was exploratory, the study was short, and the participants represented a specific medical population. Larger studies with longer follow-up are needed to determine whether these changes translate into benefits that patients can feel and experience. [2]
Stronger Evidence for Cardiovascular Benefits
While the aging research is emerging, evidence for certain cardiovascular benefits is more established.
The SELECT trial enrolled more than 17,000 adults with overweight or obesity and existing cardiovascular disease who did not have diabetes. Participants receiving semaglutide 2.4 mg weekly had a 20% lower relative risk of the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared with placebo. These events occurred in approximately 6.5% of the semaglutide group and 8% of the placebo group during follow-up. [3]
These results demonstrate a clinical benefit in the population studied. They also help explain why conversations about weight treatment increasingly include long-term health alongside weight loss.
How We Apply This Research to Your Care
Wegovy contains semaglutide, the same active ingredient evaluated in this research. However, promising findings about aging markers are not enough, on their own, to justify treatment.
Our recommendations begin with your health history, treatment goals, eligibility, and the potential benefits and risks for you. If we recommend GLP-1 therapy, we monitor your response, tolerability, nutritional intake, and progress over time.
We also pay close attention to preserving muscle. Our approach includes adequate protein, nutrient-dense meals, regular movement, and strength training tailored to your abilities. These remain priorities throughout weight management.
Within our Pillars of Health Program, medication is one part of a broader plan that addresses the factors influencing how you feel and function over time.
The possibility that GLP-1 medications may influence biological aging is exciting. For now, we use the strongest available evidence to guide care while following new research carefully. If you would like to discuss whether GLP-1 treatment fits your weight management and metabolic health goals, we would be happy to explore your options with you.
To explore a personalized plan for menopause and/or weight management, schedule an appointment with renowned menopause expert Ruthie Harper, MD in Austin, TX.
Austin, TX GLP1 Weight Loss Meds: 512-343-9355
.
Research Sources
[1] Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity: STEP 1, 2, and 3. eClinicalMedicine (2023).
https://pubmed.ncbi.nlm.nih.gov/36467859/
[2] Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nature Communications (2026).
https://www.nature.com/articles/s41467-026-72861-3
[3] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine (2023).
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
